Makuku R, Khalili N, Razi S, Keshavarz-Fathi M, Rezaei N. Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy. J Immunol Res. 2021;2021:1–15. https://doi.org/10.1155/2021/6661406.

Article  CAS  Google Scholar 

Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, preventive and personalised medicine as the hardcore of ‘Horizon 2020’: EPMA position paper. EPMA J. 2014;5:6. https://doi.org/10.1186/1878-5085-5-6.

Article  PubMed  PubMed Central  Google Scholar 

Golubnitschaja O, Watson ID, Topic E, Sandberg S, Ferrari M, Costigliola V. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J. 2013;4:12. https://doi.org/10.1186/1878-5085-4-12.

Article  PubMed  PubMed Central  Google Scholar 

Izzadeen A, Dymock L, Hoskins C. Small-scale particles showing large-scale impact in pancreatic cancer. Nanomedicine. 2023;18:1795–7. https://doi.org/10.1200/PO.23.00131.

Article  CAS  PubMed  Google Scholar 

Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:860–77. https://doi.org/10.1016/j.annonc.2022.05.009.

Article  CAS  PubMed  Google Scholar 

Serrano C, Martín-Broto J, Asencio-Pascual JM, López-Guerrero JA, Rubió-Casadevall J, Bagué S, et al. GEIS Guidelines for gastrointestinal stromal tumors. Ther Adv Med Oncol. 2023;2023:15. https://doi.org/10.1177/17588359231192388.

Article  Google Scholar 

Hagan S, Orr MCM, Doyle B. Targeted therapies in colorectal cancer—an integrative view by PPPM. EPMA J. 2013;4:3. https://doi.org/10.1186/1878-5085-4-3.

Article  PubMed  PubMed Central  Google Scholar 

Borisow N, Döring A, Pfueller CF, Paul F, Dörr J, Hellwig K. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J. 2012;3:9. https://doi.org/10.1186/1878-5085-3-9 . 

Golubnitschaja O, Costigliola V. Predictive, preventive and personalised medicine as the medicine of the future: anticipatory scientific innovation and advanced medical services. Anticipation and Medicine. Cham: Springer International Publishing; 2017. p. 69–85. https://doi.org/10.1007/978-3-319-45142-8_5

Pandey P, Khan F, Qari HA, Upadhyay TK, Alkhateeb AF, Oves M. Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4. Pharmaceuticals. 2022;15:335. https://doi.org/10.3390/ph15030335.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ostios-Garcia L, Pérez DM, Castelo B, Herradón NH, Zamora P, Feliu J, et al. Classification of anticancer drugs: an update with FDA- and EMA-approved drugs. Cancer Metastasis Rev. 2024;43:1561–71. https://doi.org/10.1007/s10555-024-10188-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Tong Z, Zhang W, Zhang W, Buzdin A, Mu X, et al. FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients. Front Oncol. 2021;11. https://doi.org/10.3389/fonc.2021.683419

Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23:39. https://doi.org/10.1208/s12248-021-00574-0.

Article  PubMed  Google Scholar 

André T, Lonardi S, Lenz HJ, Jensen LH, Van Cutsem E, Touchefeu Y, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW. Ann Oncol. 2024;35:S451–2. https://doi.org/10.1016/j.annonc.2024.08.610.

Article  Google Scholar 

Powderly J, Spira A, Kondo S, Doi T, Luke JJ, Rasco D, et al. Model informed dosing regimen and phase I results of the anti-PD-1 antibody Budigalimab (ABBV-181). Clin Transl Sci. 2021;14:277–87. https://doi.org/10.1111/cts.12855.

Article  CAS  PubMed  Google Scholar 

Aillón Albán AG, López Naveda FDLM, Guzmán Chávez IT, Arregui Ayala AC, Sivisaca Bonifaz CN. Evaluation of the efficacy of combined immune checkpoint inhibitors in advanced melanoma treatment—long term outcomes and emerging therapeutic perspectives: a narrative review. Ibero-Am J Health Sci Res. 2024;4:153–61.

Article  Google Scholar 

Shah V, Panchal V, Shah A, Vyas B, Agrawal S, Bharadwaj S. Immune checkpoint inhibitors in metastatic melanoma therapy (Review). Med Int. 2024;4:13. https://doi.org/10.3892/mi.2024.137.

Article  Google Scholar 

Wang D-R, Wu X-L, Sun Y-L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct Target Ther. 2022;7:331. https://doi.org/10.1038/s41392-022-01136-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H, et al. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;1–11. https://doi.org/10.20892/j.issn.2095-3941.2024.0055

Ibis B, Aliazis K, Cao C, Yenyuwadee S, Boussiotis VA. Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases. Front Immunol. 2023;14. https://doi.org/10.3389/fimmu.2023.1197364

Hossain MA. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024;143:113365. https://doi.org/10.1016/j.intimp.2024.113365.

Article  CAS  Google Scholar 

Buchbinder EI, Desai A. CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39:98–106. https://doi.org/10.1097/COC.0000000000000239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660–9. https://doi.org/10.1038/s41422-020-0343-4.

Article  PubMed  PubMed Central  Google Scholar 

Lee D, Cho M, Kim E, Seo Y, Cha J-H. PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders. Mol Ther. 2024. https://doi.org/10.1016/j.ymthe.2024.09.026.

Article  PubMed  PubMed Central  Google Scholar 

He C, Xing X, Chen H-Y, Gao M, Shi J, Xiang B, et al. UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. Mol Cell. 2024;84:1120-1138.e8. https://doi.org/10.1016/j.molcel.2024.01.024.

Article  CAS  PubMed  Google Scholar 

Su Y, Wang Q, Ru Y, Dong J, Li X. Zhang Z [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2022;38:1036–43.

PubMed  Google Scholar 

Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563–7. https://doi.org/10.1038/nature14011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Birnboim-Perach R, Benhar I. Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment. Int J Biol Sci. 2024;20:3911–22. https://doi.org/10.7150/ijbs.93697.

Article  PubMed  PubMed Central  Google Scholar 

Yang S, Yang X, Hou Z, Zhu L, Yao Z, Zhang Y, et al. Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma. Heliyon. 2024;10:e29215. https://doi.org/10.1016/j.heliyon.2024.e29215.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamamoto H, Watanabe Y, Arai H, Umemoto K, Tateishi K, Sunakawa Y. Microsatellite instability: a 2024 update. Cancer Sci. 2024;115:1738–48. https://doi.org/10.1111/cas.16160.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585–93. https://doi.org/10.1158/1078-0432.CCR-15-3101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bertele N, Karabatsiakis A, Buss C, Talmon A. How biomarker patterns can be utilized to identify individuals with a high disease burden: a bioinformatics approach towards predictive, preventive, and personalized (3P) medicine. EPMA J. 2021;12:507–16. https://doi.org/10.1007/s13167-021-00255-0.

Article  PubMed  PubMed Central